Abstract：
Haploidentical donor (haplo-) hematopoietic stem cell transplantation (HSCT) with post-transplantation cyclophosphamide (PTCy) is now performed on a large scale worldwide. Our patient outcomes did not completely reflect the results published by other groups. We herein present the results of 60 patients with hematologic malignancies treated homogeneously on a modified version of the standard protocol by adding ATG as an additional graft-versus-host disease (GVHD) prophylaxis measure. This was a retrospective analysis of 60 haplo-HSCT recipients using a myeloablative conditioning regimen with antithymocyte globulin and PTCy for GVHD prophylaxis. At 5 years, overall survival was 59.2%, relapse-free survival (RFS) was 48.6%, and chronic GVHD (cGVHD) and relapse-free survival was 40%. The median time to neutrophil and platelet engraftment was 16 days and 28.5 days, respectively. The rates of grade II-IV acute GVHD and extensive cGVHD were 46.7% and 23.3%, respectively. The cumulative incidence of relapse was 30%, nonrelapse mortality was 21.6%, and transplantation-related mortality was 11%. Higher Disease Risk Index and 50% HLA match were associated with lower RFS. Female donor to male recipient and older donor age were associated with an elevated risk of cGVHD. The use of PTCy might not yield the same results in different populations. Many remaining questions need to be addressed in randomized trials, including optimal graft source and donor, date of calcineurin inhibitor initiation, personalized or targeted dose of PTCy, immune reconstitution, and others.
摘要：
背景：带有PTCy的Haplo-HSCT现在在世界范围内大规模进行。我们患者的结果不能完全反映其他组公布的结果。我们在此介绍了通过添加ATG作为额外的GvHD预防措施，在标准方案的修改版本中均匀治疗的60例血液恶性肿瘤患者的结果。
方法：回顾性分析60例采用ATG和PTCy治疗GvHD的单倍体移植患者。
结果：在5年时，OS为59.2％，RFS为48.6%，CRFS为40%。ANC和血小板植入的中位时间分别为16天和28.5天。II-IV级aGvHD和广泛cGvHD分别为46.7%和23.3%。累积复发率（CIR）为30％，NRM为21.6%，TRM为11%。较高的DRI和50％HLA匹配与较低的RFS相关。女性对男性的捐赠和较高的捐赠年龄与较高的cGvHD相关。
结论：在不同群体中使用PTCy可能不会产生相同的结果。许多剩余的问题需要在随机试验中解决(最佳移植源和供体，CNI启动日期，个性化或目标剂量的PTCy，免疫重建，等。).
方法：回顾性分析60例采用ATG和PTCy治疗GvHD的单倍体移植患者。
结果：在5年时，OS为59.2％，RFS为48.6%，CRFS为40%。ANC和血小板植入的中位时间分别为16天和28.5天。II-IV级aGvHD和广泛cGvHD分别为46.7%和23.3%。累积复发率（CIR）为30％，NRM为21.6%，TRM为11%。较高的DRI和50％HLA匹配与较低的RFS相关。女性对男性的捐赠和较高的捐赠年龄与较高的cGvHD相关。
结论：在不同群体中使用PTCy可能不会产生相同的结果。许多剩余的问题需要在随机试验中解决(最佳移植源和供体，CNI启动日期，个性化或目标剂量的PTCy，免疫重建，等。).
